HC Wainwright Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $200.00

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) had its target price boosted by HC Wainwright from $190.00 to $200.00 in a report released on Thursday,Benzinga reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price target suggests a potential upside of 45.19% from the company's previous close. HC Wainwright also issued estimates for Axsome Therapeutics' Q1 2026 earnings at $0.11 EPS and FY2026 earnings at $7.52 EPS.

A number of other equities analysts have also recently issued reports on the company. Mizuho raised their target price on Axsome Therapeutics from $137.00 to $195.00 and gave the stock an "outperform" rating in a report on Tuesday, February 11th. Truist Financial raised their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a "buy" rating in a report on Wednesday. Robert W. Baird lifted their price objective on Axsome Therapeutics from $112.00 to $116.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Needham & Company LLC lifted their price objective on Axsome Therapeutics from $133.00 to $153.00 and gave the company a "buy" rating in a report on Wednesday. Finally, StockNews.com upgraded Axsome Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $155.47.

Axsome Therapeutics Trading Up 6.7 %

AXSM stock traded up $8.65 during midday trading on Thursday, reaching $137.75. The stock had a trading volume of 1,539,189 shares, compared to its average volume of 1,103,887. The company has a quick ratio of 2.37, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. Axsome Therapeutics has a twelve month low of $64.11 and a twelve month high of $139.13. The firm has a market cap of $6.72 billion, a price-to-earnings ratio of -23.00 and a beta of 1.05. The business has a fifty day simple moving average of $101.29 and a two-hundred day simple moving average of $94.84.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. The firm had revenue of $118.77 million for the quarter, compared to analysts' expectations of $117.83 million. As a group, research analysts expect that Axsome Therapeutics will post -2.26 EPS for the current fiscal year.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the business's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now owns 42,187 shares of the company's stock, valued at $5,529,450.09. The trade was a 6.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 22.40% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. BVF Inc. IL increased its position in shares of Axsome Therapeutics by 32.7% during the 4th quarter. BVF Inc. IL now owns 1,388,064 shares of the company's stock worth $117,444,000 after purchasing an additional 342,064 shares during the last quarter. FMR LLC increased its position in shares of Axsome Therapeutics by 20.6% during the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company's stock worth $97,786,000 after purchasing an additional 185,951 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Axsome Therapeutics by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 912,538 shares of the company's stock worth $77,228,000 after purchasing an additional 4,079 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Axsome Therapeutics by 1.1% during the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company's stock worth $66,750,000 after purchasing an additional 8,125 shares during the last quarter. Finally, Invesco Ltd. increased its position in shares of Axsome Therapeutics by 10.8% during the 4th quarter. Invesco Ltd. now owns 692,464 shares of the company's stock worth $58,589,000 after purchasing an additional 67,285 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.